Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus TETRACYN.
ACTICLATE CAP vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic